Passage Bio, Inc.
PASG
$4.94
$0.091.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.93M | 18.58M | 19.88M | 19.67M | 22.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.09M | 38.21M | 43.15M | 47.08M | 54.33M |
| Operating Income | -38.09M | -38.21M | -43.15M | -47.08M | -54.33M |
| Income Before Tax | -36.11M | -37.68M | -45.52M | -45.26M | -56.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.11 | -37.68 | -45.52 | -45.26 | -56.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.11M | -37.68M | -45.52M | -45.26M | -56.86M |
| EBIT | -38.09M | -38.21M | -43.15M | -47.08M | -54.33M |
| EBITDA | -37.58M | -37.55M | -42.42M | -45.81M | -52.49M |
| EPS Basic | -11.32 | -11.84 | -14.35 | -14.31 | -18.02 |
| Normalized Basic EPS | -6.89 | -6.83 | -7.76 | -8.42 | -9.79 |
| EPS Diluted | -11.32 | -11.84 | -14.35 | -14.31 | -18.02 |
| Normalized Diluted EPS | -6.89 | -6.83 | -7.76 | -8.42 | -9.79 |
| Average Basic Shares Outstanding | 12.77M | 12.73M | 12.69M | 12.66M | 12.63M |
| Average Diluted Shares Outstanding | 12.77M | 12.73M | 12.69M | 12.66M | 12.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |